Handelsavisen
prelaunch
Companies Healthcare 8279.TWO
82
8279.TWO TPEx Pharmaceuticals

8279.Two

$97,00
Open in Charts → Attach watcher ⌖
TWD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
2,6B TWD
P/E
EV / Rev
Div yield
5,05 %
Op margin
15,3 %
ROE
11,4 %
Net margin
12,7 %
Debt / equity
0,10
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

The company operates in the pharmaceuticals industry, developing and commercializing prescription drugs and therapies for various medical conditions.

Business. The company operates in the pharmaceuticals industry, developing and commercializing prescription drugs and therapies for various medical conditions.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
11,4 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 8279.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 8279.TWO. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    The company operates in the pharmaceuticals industry, developing and commercializing prescription drugs and therapies for various medical conditions.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    AI synthesis
    GENERATED

    The company maintains a conservative capital structure with a debt-to-equity ratio of 0.1, indicating a low reliance on debt financing. Its liquidity position is characterized as medium, with a current ratio of 2.2, suggesting the company has sufficient short-term assets to cover its short-term liabilities. The price-to-book ratio of 1.1 and price-to-tangible-book ratio of 1.1 indicate that the company's market value is closely aligned with its book value, suggesting a relatively stable valuation.

    In terms of profitability, the company demonstrates a return on equity (ROE) of 11.44% and a return on assets (ROA) of 8.91%, both of which are strong indicators of efficient capital utilization and asset management. These metrics suggest the company is generating solid returns relative to its equity and asset base, which is favorable compared to industry norms.

    The company's revenue is primarily concentrated in a single geographic region, as disclosed in its financial segments. While the exact breakdown of revenue by segment is not provided, the company's exposure to a single market may increase its vulnerability to regional economic fluctuations. The absence of detailed segment data limits the ability to assess diversification risks comprehensively.

    The company's growth trajectory is supported by a strong operating cash flow of 319,483,000 and a free cash flow of 193,853,000, which provides flexibility for reinvestment and shareholder returns. The capital expenditure of -63,564,000 indicates a reduction in capital spending, which may reflect a strategic shift or a focus on optimizing existing assets. The outlook for the current fiscal year suggests continued operational efficiency and potential for revenue growth.

    The company faces a medium liquidity risk, as indicated by the risk assessment, and a low dilution risk, with no significant dilution potential identified. The key risk flag of negative net cash after subtracting total debt highlights the need for careful liquidity management. The valuation adjustments applied in the custom valuations suggest a conservative approach to asset valuation, which may impact the company's market perception.

    Recent events, including financial filings and transcripts, have not revealed any material changes in the company's operations or strategic direction. The company's financial health remains stable, with no significant adverse developments reported in the latest disclosures. The absence of recent events does not indicate a lack of activity but rather a consistent and predictable operational performance.

    Key takeaways
    • The company maintains a conservative capital structure with a low debt-to-equity ratio of 0.1.
    • Strong profitability metrics, including a return on equity of 11.44% and a return on assets of 8.91%, indicate efficient capital utilization.
    • The company's liquidity position is characterized as medium, with a current ratio of 2.2.
    • The company's growth trajectory is supported by a strong operating cash flow and a reduction in capital spending.
    • The company faces a medium liquidity risk and a low dilution risk, with no significant dilution potential identified.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $97,00
    Market cap
    $2.61B
    Enterprise value
    $2.84B
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    8.9x
    P / B
    1.1x
    P / Tangible book
    1.1x
    Tangible book
    $2.37B
    Net cash
    -$231.7M
    Current ratio
    2.2
    Debt / equity
    0.1
    ROA
    8.9%
    ROE
    11.4%
    Cash conversion
    118.0%
    CapEx / revenue
    -3.0%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin15,3 %Above P75
    Net Margin12,7 %Above P75
    ROE11,4 %Above P75
    Capex / Rev-3,0 %Above median
    D/E0,10Above median
    Cash Conv1,18Above median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Ev To Operating Cash Flow
      enterprise_value / operating_cash_flow
    • Return On Equity
      net_income / total_equity
    • Price To Earnings
      market_price / (net_income / shares_outstanding_diluted)
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    Source documents
    • 8279.TWO Market data — financials · 2026-05-27

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    8279.TWOCanonical
    TPEx · TWD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage